Category: Johnson Johnson

A drug-dispensing contact lens

July 21, 2009

Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye.

Omega-3 fatty acids appear to impact AMD progression

June 18, 2009

BOSTON (June 18, 2009) - Omega-3 fatty acids found in fatty fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD), but the benefits appear to depend on the stage of disease and whether certain supplements are taken, report researchers at the Laboratory for Nutrition and Vision Research (LNVR), Jean Mayer USDA Human Nutrition Research Center on Ag

Data on investigational drug TMC207 for MDR-TB published in New England Journal of Medicine

June 3, 2009

[Mechelen Belgium, June 3, 2009] ?Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA.

FDA approves wheelchair by Segway inventor Kamen

November 25, 2002

Ibot The U.S. Food and Drug Administration has approved the sale of a new wheelchair that enables users to operate on two wheels, allowing them to better negotiate obstacles like stairs and uneven pavement. Powered by a rechargeable battery that can operate up to a full day on a single charge, the wheelchair uses an integrated system of electronic, sensor and software components to automatically adjust itself according to the seat's movement and the user's center of gravity. These components are accompanied by a backup system to assure the safety of the user. It was invented by Dean Kamen, founder of DEKA Research and Development Corporation, best known for the two-wheeled Segway transporter.

Researchers Elucidate Machinery of Major Anti-Cancer Drug Target

October 27, 2002

Researchers have detailed the functioning of an enzyme that is a central component of a signaling pathway important for about 30 percent of cancers. The findings about how the enzyme, called farnesyl transferase (FTase), works could help improve the FTase-inhibiting drugs that pharmaceutical companies are now testing to fight a broad spectrum of cancers.